Meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine (GlaxoSmithKline)

N/A

Report date: 2023/04/21 14:28:42

Base Information

Drug NameMeningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine (GlaxoSmithKline)
Drug Alias NameMenHibrix (Hib-MenCY-TT)MenHibrix
ClassificationVaccines > Biological material > Toxoid vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHaemophilus InfectionsMeningococcal Infections
Global Approved IndicationsHaemophilus InfectionsMeningococcal Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/06/14
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsHaemophilus InfectionsMeningococcal Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ07AH
Related LinksN/A